Alpha 2.0
Login Register
» Articles » PMID: 32366720

Identification of Antiviral Drug Candidates Against SARS-CoV-2 from FDA-Approved Drugs

Overview
Journal Antimicrob Agents Chemother
Publisher American Society for Microbiology
Specialty Pharmacology
Date 2020 May 6
PMID 32366720
Citations 409
Authors
Sangeun Jeon
Meehyun Ko
Jihye Lee
Inhee Choi
Soo Young Byun
Soonju Park
David Shum
Seungtaek Kim
Affiliations
Soon will be listed here.
Abstract

Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (ICs), and in particular, two FDA-approved drugs-niclosamide and ciclesonide-were notable in some respects.

Citing Articles

Unveiling the antiviral inhibitory activity of ebselen and ebsulfur derivatives on SARS-CoV-2 using machine learning-based QSAR, LB-PaCS-MD, and experimental assay.

Sinsulpsiri S, Nishii Y, Xu-Xu Q, Miura M, Wilasluck P, Salamteh K Sci Rep. 2025; 15(1):6956.

PMID: 40011571 PMC: 11865625. DOI: 10.1038/s41598-025-91235-1.

Clinical safety and pharmacokinetics of a novel oral niclosamide formulation compared with marketed niclosamide chewing tablets in healthy volunteers: A three-part randomized, double-blind, placebo-controlled trial.

Walther N, Schultz-Heienbrok R, Stass H, Corman V, Gassen N, Muller M PLoS One. 2025; 20(2):e0303924.

PMID: 39999124 PMC: 11856320. DOI: 10.1371/journal.pone.0303924.

Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V platform trial.

Humphrey T, Qian W, Chen-Xu M, Dowling F, Gatley K, Adhikari R BMC Infect Dis. 2025; 25(1):204.

PMID: 39934669 PMC: 11818026. DOI: 10.1186/s12879-025-10584-4.

In Vitro Screening of an In-House Library of Structurally Distinct Chemotypes Towards the Identification of Novel SARS-CoV-2 Inhibitors.

Tonelli M, Sparatore A, Bassanini I, Francesconi V, Sparatore F, Maina K Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770510 PMC: 11676875. DOI: 10.3390/ph17121668.

Repurposing Drugs and Synergistic Combinations as Potential Therapies for Inhibiting SARS-CoV-2 and Coronavirus Replication.

Boulon R, Mazeaud C, Farahani M, Broquiere M, Iddir M, Charpentier T ACS Pharmacol Transl Sci. 2024; 7(12):4043-4055.

PMID: 39698276 PMC: 11650740. DOI: 10.1021/acsptsci.4c00512.

References
1.
Xu J, Shi P, Li H, Zhou J . Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential. ACS Infect Dis. 2020; 6(5):909-915. PMC: 7098069. DOI: 10.1021/acsinfecdis.0c00052. View
2.
Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y . Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med. 2020; 382(13):1199-1207. PMC: 7121484. DOI: 10.1056/NEJMoa2001316. View
3.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30(3):269-271. PMC: 7054408. DOI: 10.1038/s41422-020-0282-0. View
4.
Matsuyama S, Kawase M, Nao N, Shirato K, Ujike M, Kamitani W . The Inhaled Steroid Ciclesonide Blocks SARS-CoV-2 RNA Replication by Targeting the Viral Replication-Transcription Complex in Cultured Cells. J Virol. 2020; 95(1). PMC: 7737752. DOI: 10.1128/JVI.01648-20. View
5.
Maxmen A . More than 80 clinical trials launch to test coronavirus treatments. Nature. 2020; 578(7795):347-348. DOI: 10.1038/d41586-020-00444-3. View